Stocks of Revolution Medicines Inc (NASDAQ:RVMD) traded higher last session on Wall Street, down -0.09% to $58.58.
RVMD stock price is now 13.99% away from the 50-day moving average and 41.01% away from the 200-day moving average. The market capitalization of the company currently stands at $9.85B.
With the price target enhanced from $46 to $62, Needham maintained Buy rating for Revolution Medicines Inc (NASDAQ: RVMD). On July 12, 2024, Barclays recently initiated its ‘Overweight’ rating on the stock quoting a target price of $52, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Cislini Jeff, General Counsel sold 2,554 shares of the company’s stock on Nov 15 ’24. The stock was sold for $140,811 at an average price of $55.13. Upon completion of the transaction, the General Counsel now directly owns 43,080 shares in the company, valued at $2.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 15 ’24, Officer JEFFREY TODD CISLINI bought 2,554 shares of the business’s stock. A total of $146,523 was incurred on buying the stock at an average price of $57.37. A total of 16.18% of the company’s stock is owned by insiders.
During the past 12 months, Revolution Medicines Inc has had a low of $20.98 and a high of $62.40. As of last week, the company has a debt-to-equity ratio of 0.06, a current ratio of 14.24, and a quick ratio of 14.24. The fifty day moving average price for RVMD is $51.1014 and a two-hundred day moving average price translates $41.39425 for the stock.
The latest earnings results from Revolution Medicines Inc (NASDAQ: RVMD) was released for 2024-09-30. The net profit margin was -76423.32% and return on equity was -47.18% for RVMD.
